Multi-cancer early detection (MCED) tests: prioritizing equity from bench to bedside

Multi-cancer early detection (MCED) tests are blood-based tests designed to screen for signals of multiple cancers. There is growing interest and investment in examining the potential benefits and applications of MCED tests. If MCED tests are shown to have clinical utility, it is important to ensure...

Full description

Saved in:
Bibliographic Details
Published in:Health affairs scholar 2024-05, Vol.2 (5), p.qxae039-qxae039
Main Authors: Miller, Sarah J, Sly, Jamilia R, Rolfo, Christian, Mack, Philip, Villanueva, Augusto, Mazor, Melissa, Weber, Ellerie, Lin, Jenny J, Smith, Cardinale B, Taioli, Emanuela
Format: Article
Language:English
Subjects:
Policy Inquiry
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Multi-cancer early detection (MCED) tests are blood-based tests designed to screen for signals of multiple cancers. There is growing interest and investment in examining the potential benefits and applications of MCED tests. If MCED tests are shown to have clinical utility, it is important to ensure that all people-regardless of their demographic or socioeconomic background-equitably benefit from these tests. Unfortunately, with health care innovation, such considerations are often ignored until after inequities emerge. We urge for-profit companies, scientists, clinicians, payers, and government agencies to prioritize equity now-when MCEDs are still being developed and researched. In an effort to avoid creating and exacerbating cancer inequities, we propose 9 equity considerations for MCEDs.
ISSN:2976-5390
2976-5390
DOI:10.1093/haschl/qxae039